Skip to main content
Figure 3 | Alzheimer's Research & Therapy

Figure 3

From: Requiring an amyloid-β1-42 biomarker may improve the efficiency of a study, and simulations may help in planning studies

Figure 3

Difference between a percentage placebo effect and a standardised difference (Cohen's D ). (a) Alzheimer Disease Assessment Scale - cognitive subscale (ADAS-cog) 50% placebo effect large decline. (b) ADAS-cog 50% standardised difference large decline. (c) ADAS-cog 50% placebo effect small decline. (d) ADAS-cog 50% standardised difference small decline. PBO, placebo; TRT, treatment.

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193